Replicate Bioscience Announces Publication of First-in-Human Data for Its Optimized srRNA Rabies Vaccine in Nature Communications

Results provide clinical demonstration of best-in-class immunogenicity achieved with an RNA-based platform and good tolerability

RBI-4000’s potential to offer a meaningful improvement over existing vaccines for rabies, an ongoing global public health concern, supports further development

Excerpt from the Press Release:

SAN DIEGO, Feb. 7, 2025 /PRNewswire/ — Replicate Bioscience, a clinical-stage company pioneering novel self-replicating RNA (srRNA) technology for applications across infectious disease, immunology, and other therapeutic areas, today announced that data from the Phase I study of its srRNA-based rabies vaccine candidate, RBI-4000, have been published in Nature Communications.

The article, “Safety and immunogenicity of an optimized self-replicating RNA platform for low dose or single dose vaccine applications: a randomized, open label Phase I study in healthy volunteers,” includes full data from the company’s rabies vaccine candidate, RBI-4000. The data reinforce interim Phase I results presented last year at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, which demonstrated class-leading safety and immunogenicity for Replicate’s optimized srRNA platform.

The Phase I study showed that a single dose of RBI-4000 elicited immune responses that attained a World Health Organization (WHO)-established immune threshold of protection against rabies across all dose levels tested, with good tolerability. No serious adverse events, dose-limiting toxicities, or maximum tolerated dose level were observed in the study.

Click the button below to read the entire Press Release:

Continue Reading The Press Release